Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.43 |
| ▸ | SMO | Q99835 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931884 | 0.93 | MEN1 (0.44) | MEN1KMT2APDE10ASMOSMN1; SMN2 | |
| SCHEMBL9932899 | 0.93 | MEN1 (0.44) | MEN1KMT2APDE10ASMOSMN1; SMN2 | |
| SCHEMBL9931559 | 0.92 | SMO (0.47) | MEN1KMT2APDE10ASMO | |
| SCHEMBL9932181 | 0.92 | SMO (0.47) | MEN1KMT2APDE10ASMO | |
| SCHEMBL9968363 | 0.90 | MEN1 (0.45) | MEN1KMT2APDE10ASMN1; SMN2KDM4E | |
| SCHEMBL9968385 | 0.89 | PDE10A (0.43) | MEN1KMT2APDE10ASMO | |
| SCHEMBL9968386 | 0.89 | PDE10A (0.43) | MEN1KMT2APDE10ASMO | |
| SCHEMBL9932138 | 0.89 | SMO (0.54) | MEN1KMT2APDE10ASMO | |
| SCHEMBL9968412 | 0.89 | MEN1 (0.47) | MEN1KMT2APDE10ASMOSMN1; SMN2 | |
| SCHEMBL12841522 | 0.89 | MEN1 (0.47) | MEN1KMT2APDE10ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | MEN1 1168/4885KMT2A 310/4885PDE10A 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.